These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 29540641)
1. Management of Anaplastic Thyroid Carcinoma: the Fruits from the ATC Research Consortium of Japan. Sugitani I; Onoda N; Ito KI; Suzuki S J Nippon Med Sch; 2018; 85(1):18-27. PubMed ID: 29540641 [TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. Sugitani I; Miyauchi A; Sugino K; Okamoto T; Yoshida A; Suzuki S World J Surg; 2012 Jun; 36(6):1247-54. PubMed ID: 22311136 [TBL] [Abstract][Full Text] [Related]
3. [The anaplastic thyroid carcinoma research consortium of Japan]. Sugitani I Nihon Geka Gakkai Zasshi; 2012 Jul; 113(4):368-72. PubMed ID: 22928442 [TBL] [Abstract][Full Text] [Related]
4. Concept and design of a nationwide prospective feasibility/efficacy/safety study of weekly paclitaxel for patients with pathologically confirmed anaplastic thyroid cancer (ATCCJ-PTX-P2). Onoda N; Sugitani I; Higashiyama T; Hara H; Ito K; Kammori M; Sugino K; Suzuki S; Toda K; Yoshida A; Miyauchi A BMC Cancer; 2015 Jun; 15():475. PubMed ID: 26091846 [TBL] [Abstract][Full Text] [Related]
5. Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe. Barbaro D; Lapi P; Viacava P; Torregrossa L BMJ Case Rep; 2020 Dec; 13(12):. PubMed ID: 33370973 [TBL] [Abstract][Full Text] [Related]
8. Anaplastic thyroid carcinomas incidentally found on postoperative pathological examination. Yoshida A; Sugino K; Sugitani I; Miyauchi A World J Surg; 2014 Sep; 38(9):2311-6. PubMed ID: 24687351 [TBL] [Abstract][Full Text] [Related]
9. Anaplastic thyroid cancer. Ranganath R; Shah MA; Shah AR Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):387-91. PubMed ID: 26313900 [TBL] [Abstract][Full Text] [Related]
10. Role of surgery in the management of anaplastic thyroid carcinoma: Korean nationwide multicenter study of 329 patients with anaplastic thyroid carcinoma, 2000 to 2012. Baek SK; Lee MC; Hah JH; Ahn SH; Son YI; Rho YS; Chung PS; Lee YS; Koo BS; Jung KY; Lee BJ Head Neck; 2017 Jan; 39(1):133-139. PubMed ID: 27534388 [TBL] [Abstract][Full Text] [Related]
11. Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer. Yamazaki H; Yokose T; Hayashi H; Iwasaki H; Osanai S; Suganuma N; Nakayama H; Masudo K; Rino Y; Masuda M Cancer Chemother Pharmacol; 2018 Oct; 82(4):649-654. PubMed ID: 30051190 [TBL] [Abstract][Full Text] [Related]
12. Treatment and Prognosis of Anaplastic Thyroid Carcinoma: A Clinical Study of 50 Cases. Liu TR; Xiao ZW; Xu HN; Long Z; Wei FQ; Zhuang SM; Sun XM; Xie LE; Mu JS; Yang AK; Zhang GP; Fan Y PLoS One; 2016; 11(10):e0164840. PubMed ID: 27760217 [TBL] [Abstract][Full Text] [Related]
13. The Safety and Efficacy of Weekly Paclitaxel Administration for Anaplastic Thyroid Cancer Patients: A Nationwide Prospective Study. Onoda N; Sugino K; Higashiyama T; Kammori M; Toda K; Ito K; Yoshida A; Suganuma N; Nakashima N; Suzuki S; Tsukahara K; Noguchi H; Koizumi M; Nemoto T; Hara H; Miyauchi A; Sugitani I Thyroid; 2016 Sep; 26(9):1293-9. PubMed ID: 27484330 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE). Higashiyama T; Sugino K; Hara H; Ito KI; Nakashima N; Onoda N; Tori M; Katoh H; Kiyota N; Ota I; Suganuma N; Hibi Y; Nemoto T; Takahashi S; Yane K; Ioji T; Kojima S; Kaneda H; Sugitani I; Tahara M Eur J Cancer; 2022 Sep; 173():210-218. PubMed ID: 35932627 [TBL] [Abstract][Full Text] [Related]
15. Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma. Lee DY; Won JK; Lee SH; Park DJ; Jung KC; Sung MW; Wu HG; Kim KH; Park YJ; Hah JH Thyroid; 2016 Mar; 26(3):404-13. PubMed ID: 26541309 [TBL] [Abstract][Full Text] [Related]
16. A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib. Hamamoto T; Kono T; Taruya T; Ishino T; Ueda T; Takeno S Auris Nasus Larynx; 2022 Jun; 49(3):515-519. PubMed ID: 33109426 [TBL] [Abstract][Full Text] [Related]
17. Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma. Gómez Sáez JM; Jiménez-Fonseca P; Santamaría Sandi J; Capdevila Castillón J; Navarro González E; Zafón Llopis C; Ramón Y Cajal Asensio T; Riesco Eizaguirre G; Grande Pulido E; Galofré Ferrater JC Endocrinol Nutr; 2015 Mar; 62(3):e15-22. PubMed ID: 25583658 [TBL] [Abstract][Full Text] [Related]
18. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan. Takahashi S; Tahara M; Ito K; Tori M; Kiyota N; Yoshida K; Sakata Y; Yoshida A Adv Ther; 2020 Sep; 37(9):3850-3862. PubMed ID: 32676927 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer. Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187 [TBL] [Abstract][Full Text] [Related]
20. Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. Wendler J; Kroiss M; Gast K; Kreissl MC; Allelein S; Lichtenauer U; Blaser R; Spitzweg C; Fassnacht M; Schott M; Führer D; Tiedje V Eur J Endocrinol; 2016 Dec; 175(6):521-529. PubMed ID: 27926471 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]